02252 PE Ratio & Valuation, Is 02252 Overvalued

Historical Valuation

MEDBOT-B (02252) is now in the Overvalued zone, suggesting that its current forward PS ratio of 28.87 is considered Overvalued compared with the five-year average of -40.88. The fair price of MEDBOT-B (02252) is between 17.37 to 25.38 according to relative valuation method. Compared to the current price of 25.50 USD , MEDBOT-B By Overvalued By 0.47%.

Relative Value

Fair Zone

17.37-25.38

Current Price：25.50

0.47%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is MEDBOT-B (02252) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

MEDBOT-B (02252) has a current Price-to-Book (P/B) ratio of 42.87. Compared to its 3-year average P/B ratio of 35.86, the current P/B ratio is approximately 19.55% higher. Relative to its 5-year average P/B ratio of 29.10, the current P/B ratio is about 47.33% higher. MEDBOT-B (02252) has a Forward Free Cash Flow (FCF) yield of approximately -1.03%. Compared to its 3-year average FCF yield of -4.20%, the current FCF yield is approximately -75.42% lower. Relative to its 5-year average FCF yield of -3.82%, the current FCF yield is about -73.03% lower.

Performance Decomposition

AI Analysis

Market capitalization of 02252 increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of 02252 in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is 02252 currently overvalued or undervalued?

What is MEDBOT-B (02252) fair value?

02252's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of MEDBOT-B (02252) is between 17.37 to 25.38 according to relative valuation method.

How does 02252's valuation metrics compare to the industry average?

The average P/S ratio for 02252's competitors is 0.00, providing a benchmark for relative valuation. MEDBOT-B Corp (02252) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for MEDBOT-B (02252) as of Mar 06 2026?

As of Mar 06 2026, MEDBOT-B (02252) has a P/B ratio of 42.87. This indicates that the market values 02252 at 42.87 times its book value.

What is the current FCF Yield for MEDBOT-B (02252) as of Mar 06 2026?

As of Mar 06 2026, MEDBOT-B (02252) has a FCF Yield of -1.03%. This means that for every dollar of MEDBOT-B's market capitalization, the company generates -1.03 cents in free cash flow.

What is the current Forward P/E ratio for MEDBOT-B (02252) as of Mar 06 2026?

As of Mar 06 2026, MEDBOT-B (02252) has a Forward P/E ratio of -138.85. This means the market is willing to pay $-138.85 for every dollar of MEDBOT-B's expected earnings over the next 12 months.

What is the current Forward P/S ratio for MEDBOT-B (02252) as of Mar 06 2026?

As of Mar 06 2026, MEDBOT-B (02252) has a Forward P/S ratio of 28.87. This means the market is valuing 02252 at $28.87 for every dollar of expected revenue over the next 12 months.

02252 Valuation